Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) have received an average rating of “Hold” from the twenty-one ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $34.58.
Several equities research analysts recently commented on RARE shares. Wall Street Zen raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. William Blair lowered shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 3rd. Citigroup lifted their target price on shares of Ultragenyx Pharmaceutical from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, September 18th. Royal Bank Of Canada downgraded shares of Ultragenyx Pharmaceutical from a “moderate buy” rating to a “hold” rating in a research report on Thursday, September 3rd. Finally, Cantor Fitzgerald increased their price target on shares of Ultragenyx Pharmaceutical from $33.00 to $39.00 and gave the stock an “overweight” rating in a research note on Friday, September 18th.
View Our Latest Report on RARE
Ultragenyx Pharmaceutical Trading Down 1.8%
Shares of NASDAQ:RARE opened at $14.50 on Friday. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -2.48 and a beta of 0.31. Ultragenyx Pharmaceutical has a 1 year low of $12.73 and a 1 year high of $39.89. The business has a fifty day simple moving average of $22.24 and a 200 day simple moving average of $24.18.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The firm had revenue of $214.00 million for the quarter, compared to the consensus estimate of $183.08 million. During the same quarter in the previous year, the company posted ($1.17) earnings per share. The business’s quarterly revenue was up 28.5% compared to the same quarter last year. On average, sell-side analysts forecast that Ultragenyx Pharmaceutical will post -4.29 EPS for the current year.
Hedge Funds Weigh In On Ultragenyx Pharmaceutical
Several institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in shares of Ultragenyx Pharmaceutical in the second quarter valued at approximately $355,746,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Ultragenyx Pharmaceutical in the second quarter worth $6,397,000. Deutsche Bank AG bought a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth $5,503,000. Corient Private Wealth LP bought a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth $4,644,000. Finally, Blue Owl Capital Holdings LP acquired a new position in Ultragenyx Pharmaceutical in the 2nd quarter valued at $6,098,000. 97.67% of the stock is currently owned by institutional investors.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company’s work includes therapies for genetic, metabolic and skeletal disorders, with an emphasis on conditions that have limited or no effective treatment options.
Ultragenyx’s marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Dojolvi (triheptanoin), a medical food for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab), a treatment for homozygous familial hypercholesterolemia.
Featured Articles
- Five stocks we like better than Ultragenyx Pharmaceutical
- Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
- Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
- Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
- Oil May Be Stronger Than It Looks—And Diamondback Is on Sale
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Ultragenyx Pharmaceutical Right Now?
Before you consider Ultragenyx Pharmaceutical, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Ultragenyx Pharmaceutical wasn’t on the list.
While Ultragenyx Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
